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Abstract
Background: Glucagon-like peptide 2 (GLP-2) is a potent epithelium-specific intestinal growth factor. The aim of
this study was to demonstrate the prolonged effect of GLP-2 on the growth performance of weaned piglets. Forty
piglets weaned at the age of 28 d with an average BW of 6.8 ± 0.4 kg were assigned to four treatments: (i) non-
challenged control; (ii) LPS-challenged control; (iii) LPS + low GLP-2; and (iv) LPS + high GLP-2. Piglets in groups (i),
(ii), and (iv) were s.c. injected with PBS supplemented with human [Gly2]GLP-21-34 at doses of 0, 2 and 10 nmol/kg
BW per day for seven consecutive days. BW, gain:feed ratio (G:F), and plasma GLP-2 levels were determined on d 0,
7, and 14 after weaning. Piglets were challenged with i.p. administration of Escherichia coli lipopolysaccharide (LPS)
at a dose of 100 μg/kg on d 14 to induce intestinal damage. Twenty-four hours later, intestinal tract samples were
collected to assess intestinal morphology and quantify enzyme activity.
Results: Plasma GLP-2 levels decreased after weaning, but in the high GLP-2 group, plasma GLP-2 was maintained
on d 7 and even increased to a level higher than the preweaning level on d 14 (P < 0.05). High GLP-2 treatment
significantly increased the duodenal, jejunal and ileal weight, as well as the gross weight of the small intestine (SI),
and the SI weight index (P < 0.05). LPS caused villous atrophy and disrupted intestinal morphology in the
duodenum, jejunum and ileum. GLP-2 also significantly increased the villus height and the villus height/crypt
depth ratio (VCR) of the duodenum, jejunum, and ileum (P < 0.05). Histological examination revealed that in
GLP-2-treated groups, the integrity of the villus was maintained, and the villus was protected against LPS-induced
damage. GLP-2 significantly increased the activity of alkaline phosphatase (AKP), γ-glutamyltranspeptidase (γ-GT), and
pancreatic lipase in the duodenum and jejunum (P < 0.05). GLP-2 treatment also significantly increased the average
daily gain (ADG) and G:F of piglets at 0 to 7, 7 to 14, as well as 0 to14 d (P < 0.05), resulting in a significant increase of
final BW in high GLP-2 pigs (P = 0.016).
Conclusions: Exogenous GLP-2 improved the growth of weaned piglets and protected them against LPS-induced
intestinal damage. These effects may be due to the ability of GLP-2 to promote the secretion of endogenous GLP-2 to
stimulate the small intestinal development.
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Background
Postweaning intestinal disorders, characterized by de-
creased intestinal enzyme activity and abnormal intes-
tinal morphology, cause serious economic losses in the
swine industry. Digestive enzymes such as trypsin, amyl-
ase, and lipase are reported to exhibit minimum activity
at 5 d postweaning, resulting in poor digestibility [1].
Prevention of intestinal villous atrophy can improve the
growth performance of weaned piglets by enhancing nu-
trient digestion and absorption [2]. Glucagon-like pep-
tide 2 (GLP-2), a 33-amino-acid proglucagon-derived
peptide, is a specific intestinotrophic hormone secreted
from enteroendocrine L cells. It has been shown to im-
prove intestinal structure development in fetal and neo-
natal piglets [3, 4] and also to play a regulatory role in
intestinal adaptation in obese mice [5]. Plasma GLP-2
concentration was reported to decrease with weaning-
related anorexia and increase with resumption of feed
intake [6], indicating that GLP-2 may play a role in the
growth of the small intestine during weaning via a re-
sponse to enteral nutrition. Considering that GLP-2 can
enhance the proliferation and differentiation of epithelial
cells [7], we hypothesize that exogenous GLP-2 can im-
prove the growth performance of weaned piglets and
protect their intestinal mucosa from stress damage after
weaning by increasing the secretion of endogenous GLP-
2 and promoting intestinal development. Currently there
is limited research on the effects of GLP-2 on the en-
dogenous GLP-2 secretion and growth in weaned piglets.
In the present study, Escherichia coli lipopolysaccharide
(LPS) was injected into piglets to establish an intestinal
injury model, as was previously reported by Liu et al. [8].
The aim of this study was to investigate the prolonged
effects of exogenous GLP-2 on growth, intestinal morph-
ology, and enzyme activity in weaned piglets challenged
with LPS.
Methods
Animal care and diets
Animal care protocols and experimental procedures in
this study were approved by the Animal Care and Use
Committee of Sichuan Agricultural University. Forty
castrated male crossbred piglets (Duroc × Landrace ×
Yorkshire) with average initial BW of 6.8 ± 0.4 kg were
selected from eight litters and weaned at 28-day of age.
The piglets had access to a commercial cereal-based diet
(Cargill, China) from 21-day of age. Animals were
housed individually with free access to water and feed.
They were fed four times daily at approximately 0700 h,
1100 h, 1500 h, and 1900 h, with surplus feed (10~15 g)
left in the trough feeder each time. The animals were
housed in an environmentally regulated nursery main-
tained at a temperature of 26 °C.
Experimental design
At 28-day of age (the weaning day), piglets were
assigned to four treatments: (i) non-challenged control
(control; piglets injected with sterile saline on d 14 post-
weaning); (ii) LPS-challenged control (LPS; piglets
injected with sterile PBS solution containing 0 nmol/kg
BW human GLP-2 analog (h[Gly2]GLP-21-34) during the
first 7 d postweaning, and then challenged by injection
with LPS on d 14 postweaning); (iii and iv) low and high
GLP-2 groups (piglets injected with PBS solution con-
taining h[Gly2]GLP-21-34 at doses of 2 and 10 nmol/kg
BW per day for the first 7-day after weaning [3], and
then challenged by injection with LPS on d 14 postwean-
ing). The PBS solutions containing h[Gly2]GLP-21-34
(Phoenix Pharmaceuticals, Inc., USA, purity ≥ 95 %
[HPLC]) for the three treatments (excluding control)
were prepared based on an initial BW of 6.8 kg with an
injection vol of 1 mL. These solutions were s.c. injected
at the nape twice daily at 0800 h and 2000 h. Each ex-
perimental group comprised ten piglets, with one piglet
per pen, treated over a 15-day period. In this study, d 0
was the weaning day. On d 14 postweaning, the piglets
were treated with an i.p. injection of LPS (100 μg/kg
BW, Sigma, USA) dissolved in sterile saline to establish
an intestinal injury model. According to the previous
study by Zhu et al. [9], to avoid the possible effects of
LPS-induced feed intake reduction on intestinal charac-
teristics, all piglets in the four treatment groups received
20 g feed/kg BW during 14–15 d (post-challenge). BW
and feed intake were determined on d 7 and 14 post-
weaning to evaluate the average daily gain (ADG), aver-
age daily feed intake (ADFI), and gain:feed ratio (G:F).
Blood and intestinal sample collection
The time flow chart for treatment and sample collection
is shown in Fig. 1. On d 0, 7, and 14, fasting blood was
collected from the vena cava after an overnight fast for
determination of GLP-2 concentration. Blood samples
were kept in precooled vials containing EDTA (2 mg per
mL of blood) and aprotinin (400 kIU per mL of blood),
and were gently rocked several times to inhibit the activ-
ity of proteinases. The blood was centrifuged at 1500 × g
for 15 min at 4 °C to collect the plasma. Plasma samples
were then stored at -20 °C. Plasma GLP-2 concentra-
tions were determined using a commercial RIA kit
Fig. 1 The time flow chart for treatment and sample collection
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(Phoenix Pharmaceuticals, Inc., USA). This assay recog-
nizes the synthetic form of the human and porcine GLP-
2 peptides.
Twenty-four hours after the administration of LPS (on
d 15), all pigs were sacrificed by sodium pentobarbital
anesthesia (50 mg/kg BW, i.v.). The abdomen was
quickly opened, and the gastro-intestinal tract was dis-
sected and cleaned. Each segment of small intestine was
then gently blotted dry and weighed. After digesta con-
tent was collected, 20-cm segments were excised from
both the mid-duodenum and mid-jejunum to collect
mucosal samples by glass slide scraping. Digesta content
and mucosal samples were placed in cryovials and frozen
in liquid nitrogen for enzyme activity assays. A 4-cm
segment was obtained from the mid-duodenum, mid-
ileum, and mid-jejunum for subsequent histological ana-
lysis. These samples were rinsed with 0.1 mol/L PBS at
pH 7.2, and then fixed with 4 % polyformaldehyde.
Enzyme activity assay
Enzyme extracts were prepared from intestinal mucosa
using a procedure modified from Moffa et al. [10]. The
mucosa was manually homogenized with a cold glass/
glass homogenizer and then disrupted by an ultrasonic
cell-break method in 10 vol (wt/vol) of ice-cold sodium
chloride solution (0.1 mol/L). The homogenates and
digesta were centrifuged at 20,000 × g for 30 min at 4 °C,
and the supernatants were collected for determination of
protein content and enzyme activity. The enzyme activ-
ity level for each sample was normalized against the cor-
responding total protein content and was expressed as
units per gram or milligram of protein. The intestinal
digesta and mucosal protein concentrations were deter-
mined using a Coomassie (Bradford) protein assay kit
(Thermo Scientific Pierce Protein Research Products,
USA). Bovine serum albumin was used as the protein
standard. Enzyme activity was determined using com-
mercial colorimetric assay kits (Nanjing Jiancheng Bio-
engineering Institute, China). One unit of alkaline
phosphatase (AKP) activity was defined as the activity
liberating 1 mg phenol in 15 min at 37 °C per gram of
intestinal mucosal protein. One unit of Na+-K+-ATPase
was defined as the amount of ATPase that hydrolyzes
ATP to yield 1 μmol inorganic phosphorus per hour per
milligram of mucosal protein at 37 °C. One unit of γ-
glutamyltranspeptidase (γ-GT) activity was defined as
the activity liberating 1 μmol of paranitroaniline in
10 min at 37 °C per milligram of intestinal mucosal pro-
tein. One unit of amylase activity was defined as the ac-
tivity hydrolyzing 10 mg starch in 30 min at 37 °C per
milligram of intestinal digesta protein. One unit of lipase
activity was defined as the activity hydrolyzing 1 μmol
triacylglycerol in 1 min at 37 °C per gram of intestinal
digesta protein.
Morphological analysis
Paraffin sections (4 μm thick) were prepared from
polyformaldehyde-fixed samples of the duodenum, je-
junum, and ileum, and were stained with hematoxylin
and eosin. The mucosal structure was observed using a
Nikon 50i-BF fluorescent biomicroscope (Nikon Co.,
Japan), and feature dimensions were measured using
Image-Pro Plus (IPP) image analysis software. At a mag-
nification of 100 ×, the villus height and crypt depth of
ten well-oriented villi were measured. Villus height was
measured from the crypt opening to the tip of the villus,
while crypt depth was measured from the base of the
crypt to the level of the opening [11]. Values are
expressed as means from ten adjacent villi. The villus
height/crypt depth ratio (VCR) was calculated.
Statistical analysis
Data for the four treatment groups was analyzed using
SPSS 17.0 statistical software. Data was first analyzed by
one-way ANOVA with GLP-2 injection dose as a main
effect, followed by a LSD means comparison test to
compare the differences among treatments. The differ-
ence was considered significant if P < 0.05.
Results
Growth performance
BW, ADFI, ADG, and G:F (pre-LPS challenge) are
shown in Table 1. The low GLP-2 treatment resulted
in a trend of increased final BW (P = 0.061), whereas
high GLP-2 significantly increased the final BW com-
pared with the pre-LPS pigs (P = 0.022). No significant
difference in ADFI was observed regardless of the
treatment. However, both low and high GLP-2 treat-
ments significantly increased ADG at 0 to 7 (P = 0.013
and 0.019), 7 to 14 (P = 0.052 and 0.004), and 0 to 14 d
(P = 0.018 and 0.003). After the first 7-day period, low
and high doses of GLP-2 significantly increased the
G:F by 18.78 % and 20.81 %, respectively, compared to
the pre-LPS group (P < 0.001 and P < 0.001). After the
last 7-day of the experiment, low and high doses of
GLP-2 increased the G:F by 16.54 % and 26.47 %, re-
spectively (P = 0.005 and P < 0.001). Overall, during
the 14-day experimental period, low and high doses of
GLP-2 increased the G:F by 17.43 % and 23.67 %, re-
spectively (P = 0.001 and P < 0.001).
Plasma GLP-2 concentration
To investigate the endogenous GLP-2 secretion, the
basal level of plasma GLP-2 was examined. Plasma GLP-
2 concentrations for the four treatment groups (pre-LPS
challenge) are shown in Table 2. Plasma GLP-2 levels
changed significantly after weaning. In the control and
low GLP-2 groups, plasma GLP-2 was decreased signifi-
cantly on d 7 (P < 0.001 and P < 0.001) and subsequently
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increased to the weaning level on d 14 (P = 0.231 and
0.055). In the pre-LPS group (injected with sterile PBS),
the plasma GLP-2 level was significantly lower than the
weaning level on d 7 and 14 postweaning (P < 0.001 and
P = 0.006). However, in the high GLP-2 group, plasma
GLP-2 was maintained on d 7 (P = 0.522) and then in-
creased to a higher level on d 14 than that was on the
weaning day (P < 0.001). Compared with the pre-LPS
group, the reduction of plasma GLP-2 level on d 7
postweaning was suppressed by both GLP-2 injections
(P < 0.001and P < 0.001). The plasma GLP-2 level in
the low and high GLP-2-treated groups was
significantly higher than that of the pre-LPS group on
d 14 postweaning (P = 0.001 and P < 0.001).
Intestinal weight and morphology
The effects of hGLP-2 on the weight of the duodenum,
jejunum, and ileum after LPS challenge are shown in
Table 3. LPS challenge significantly decreased the duo-
denal, jejunal and ileal weight, as well as the gross
weight of SI, and the SI weight index compared with the
control pigs (P = 0.008, 0.034, 0.035, 0.017 and 0.016).
The low GLP-2 treatment significantly increased the
duodenal and jejunal weight, as well as the gross weight





Control LPS LPS + Low GLP-2 LPS + High GLP-2 1 2 3
Initial BW, kg 6.78 6.82 6.82 6.78 0.068 0.824 0.980 0.844
Final BW, kg 9.61 9.41 9.98 10.11 0.11 0.499 0.061 0.022
d 0 to 7
ADFI, g/d 320 321 320 312 7 0.966 0.943 0.691
ADG, g/d 183 174 205 203 5 0.465 0.013 0.019
G:F 0.574 0.543 0.645 0.656 0.012 0.237 <0.001 <0.001
d 7 to 14
ADFI, g/d 379 355 380 394 9 0.360 0.340 0.148
ADG, g/d 221 195 245 272 10 0.306 0.052 0.004
G:F 0.583 0.544 0.634 0.688 0.013 0.198 0.005 <0.001
d 0 to 14
ADFI, g/d 350 338 350 353 7 0.558 0.552 0.468
ADG, g/d 202 184 225 237 7 0.297 0.018 0.003
G:F 0.579 0.545 0.640 0.674 0.012 0.196 0.001 <0.001
aGLP-2 = Glucagon-like peptide 2; LPS = Escherichia coli lipopolysaccharide
bControl: non-challenged control; LPS: pigs injected with sterile PBS solution containing 0 nmol/kg BW human GLP-2; LPS + Low and LPS + High GLP-2: piglets
injected with PBS solution containing h[Gly2]GLP-21-34 at doses of 2 and 10 nmol/kg BW per day for the first 7 d after weaning. The data were obtained before
LPS challenge
cContrast: (1) control v. LPS; (2) LPS v. LPS + Low GLP-2; (3) LPS v. LPS + High GLP-2; Values are means of ten replicates





Control LPS LPS + Low GLP-2 LPS + High GLP-2 1 2 3
d 0 199.8 202.1 200.7 201.6 1.7 0.646 0.773 0.921
d 7 169.4 164.2 179.9 195.2 2.2 0.120 <0.001 <0.001
d 14 195.1 190.6 210.4 230.1 3.1 0.397 0.001 <0.001
Pooled SEM 2.9 3.3 3.0 3.5 – – – –
Contrastc 1 <0.001 <0.001 <0.001 0.522 – – –
2 <0.001 <0.001 <0.001 <0.001 – – –
3 0.231 0.006 0.055 <0.001 – – –
aGLP-2 = Glucagon-like peptide 2; LPS = Escherichia coli lipopolysaccharide
bControl: non-challenged control; LPS: pigs injected with sterile PBS solution containing 0 nmol/kg BW human GLP-2; LPS + Low and LPS + High GLP-2: piglets
injected with PBS solution containing h[Gly2]GLP-21-34 at doses of 2 and 10 nmol/kg BW per day for the first 7 d after weaning. The data were obtained before
LPS challenge
cContrast: (1) 0 d v. 7 d; (2) 7 d v. 14 d; (3). 0 d v.14 d
dContrast: (1) control v. LPS; (2) LPS v. LPS + Low GLP-2; (3) LPS v. LPS + High GLP-2; Values are means of ten replicates
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of SI (P = 0.019, 0.042 and 0.026). The high GLP-2
dose significantly increased the duodenal, jejunal and
ileal weight, as well as the gross weight of SI, and the
SI weight index (P = 0.005, 0.003, 0.001, 0.001 and
0.015). The morphology of the duodenum, jejunum,
and ileum after LPS challenge are shown in Table 4.
Compared with control pigs, LPS pigs had lower villus
height (P < 0.001, P = 0.001 and P < 0.001), and lower
VCR (P < 0.001, P = 0.005 and P < 0.001) in the duode-
num, jejunum and ileum. However, LPS did not affect
crypt depth in the duodenum, jejunum and ileum. The
low GLP-2 treatment significantly increased duodenal,
jejunal and ileal villus height (P < 0.001, P = 0.019 and
0.041), and duodenal VCR (P < 0.001) when compared
to the LPS group. The high GLP-2 treatment induced
a significant increase of duodenal, jejunal and ileal vil-
lus height (P < 0.001, P < 0.001 and P < 0.001) and
VCR (P < 0.001, P = 0.002 and P < 0.001) compared
with LPS pigs. Figure 2 shows the micrographs of the
duodenal, jejunal, and ileal villi in the control, LPS,
and GLP-2 groups after LPS challenge. In general,
blunted and shortened villi were observed in the LPS
groups (panels B, F and J), while well-developed,
finger-like, longer villi were observed in the GLP-2
groups. The LPS groups exhibited LPS-damaged villi
with erosion of the surface epithelium at the apex of
the villi (panels B, F and J). However, in the groups
pretreated with GLP-2, the integrity of intestinal
morphology was largely maintained. Glucagon-like
peptide 2 supplementation therefore prevented the in-
testinal mucosal injury caused by LPS.
Enzyme activity
The effect of GLP-2 injection on enzyme activity in the
small intestine of LPS-challenged weaned piglets is
shown in Table 5. Compared with the control group,





Control LPS LPS + Low GLP-2 LPS + High GLP-2 1 2 3
Duodenum, g 17.8 15.2 17.4 17.9 0.4 0.008 0.019 0.005
Jejunum, g 325 287 323 342 7 0.034 0.042 0.003
Ileum, g 43.8 38.5 42.2 47.1 1 0.035 0.134 0.001
Gross weight of SI, g 386 340 383 407 7 0.017 0.026 0.001
SI weight index 0.0402 0.0362 0.0385 0.0402 0.0006 0.016 0.147 0.015
aGLP-2 = Glucagon-like peptide 2; LPS = Escherichia coli lipopolysaccharide; SI = Small intestine; SI weight index = Gross weight of SI/BW
bControl: piglets injected with sterile saline on d 14 postweaning; LPS: pigs challenged by LPS on d 14 postweaning; LPS + Low and LPS + High GLP-2: piglets
pretreated with GLP-2 at doses of 2 and 10 nmol/kg BW per day for the first 7 d after weaning were challenged by LPS on d 14 postweaning. The data were
obtained 24 h after injection with LPS and 15 d post-weaning
cContrast: (1) control v. LPS; (2) LPS v. LPS + Low GLP-2; (3) LPS v. LPS + High GLP-2; Values are means of ten replicates





Control LPS LPS + Low GLP-2 LPS + High GLP-2 1 2 3
Duodenum
Villus height, μm 438 335 420 438 8 <0.001 <0.001 <0.001
Crypt depth, μm 242 257 264 237 3 0.094 0.415 0.027
VCR 1.81 1.31 1.60 1.85 0.04 <0.001 <0.001 <0.001
Jejunum
Villus height, μm 341 284 322 353 7 0.001 0.019 <0.001
Crypt depth, μm 210 207 227 212 3 0.708 0.017 0.477
VCR 1.63 1.38 1.43 1.67 0.03 0.005 0.607 0.002
Ileum
Villus height, μm 306 239 259 324 6 <0.001 0.041 <0.001
Crypt depth, μm 199.5 205.3 209.9 209.0 1.8 0.259 0.377 0.863
VCR 1.54 1.16 1.24 1.56 0.03 <0.001 0.237 <0.001
aGLP-2 = Glucagon-like peptide 2; LPS = Escherichia coli lipopolysaccharide; VCR = Villus height/Crypt depth ratio
bControl: piglets injected with sterile saline on d 14 postweaning; LPS: pigs challenged by LPS on d 14 postweaning; LPS + Low and LPS + High GLP-2: piglets
pretreated with GLP-2 at doses of 2 and 10 nmol/kg BW per day for the first 7 d after weaning were challenged by LPS on d 14 postweaning. The data were
obtained 24 h after injection with LPS and 15 d post-weaning
cContrast: (1) control v. LPS; (2) LPS v. LPS + Low GLP-2; (3) LPS v. LPS + High GLP-2; Values are means of ten replicates
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Fig. 2 GLP-2 pretreatment maintained the integrity of the villus, and protected it against LPS-induced damage. Micrographs of duodenal (a, b, c, d), jejunal
(e, f, g, h), and ileal (i, j, k, l) villi from control, LPS-treated, and GLP-2-treated piglets at 15 d postweaning. Control group (a, e, i); LPS
group (b, f, j); 2 nmol/kg GLP-2 group (c, g, k); and 10 nmol/kg GLP-2 group (d, h, l). The arrows in panels b, f and j indicate the damaged
tips of the intestinal villi after LPS treatment. Desquamation was observed at the tips of the intestinal villi, and the exposed lamina propria
was clearly seen in the control group (panels b, f and j). (100 ×)





Control LPS LPS + Low GLP-2 LPS + High GLP-2 1 2 3
Duodenum
Na+-K+-ATPase, U/mg protein 541 511 536 522 18 0.573 0.636 0.828
AKP, U/mg protein 47.6 27.3 42.1 49.6 1.8 <0.001 <0.001 <0.001
γ-GT, U/g protein 1,035 872 1,015 1,117 30 0.045 0.079 0.004
Amylase, U/mg protein 74.5 67.6 74.3 76.3 1.3 0.060 0.068 0.019
Lipase, U/mg protein 17,777 15,227 17,792 19,608 435 0.020 0.019 <0.001
Jejunum
Na+-K+-ATPase, U/mg protein 566 524 524 532 13 0.275 0.996 0.829
AKP, U/mg protein 15.4 12.4 14.4 16.5 0.5 0.047 0.178 0.007
γ-GT, U/g protein 988 818 945 1,013 26 0.019 0.075 0.008
Amylase, U/mg protein 154 144 166 161 4.7 0.467 0.103 0.215
Lipase, U/mg protein 48,436 38,616 44,289 52,209 1695 0.031 0.204 0.004
aGLP-2 = Glucagon-like peptide 2; LPS = Escherichia coli lipopolysaccharide; AKP = Alkaline phosphatase; γ-GT = γ-Glutamyltranspeptidase
bControl: piglets injected with sterile saline on d 14 postweaning; LPS: pigs challenged by LPS on d 14 postweaning; LPS + Low and LPS + High GLP-2: piglets
pretreated with GLP-2 at doses of 2 and 10 nmol/kg BW per day for the first 7 d after weaning were challenged by LPS on d 14 postweaning. The data were
obtained 24 h after injection with LPS and 15 d post-weaning
cContrast: (1) control v. LPS; (2) LPS v. LPS + Low GLP-2; (3) LPS v. LPS + High GLP-2; Values are means of ten replicates
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piglets in the LPS group exhibited decreased activity
of AKP, γ-GT, and pancreatic lipase in the duodenum
(P < 0.001, P = 0.045 and 0.020) and jejunum (P = 0.047,
0.019 and 0.031). The high GLP-2 treatment significantly
increased the activity of AKP, γ-GT, pancreatic amylase and
lipase in the duodenum (P < 0.001, P = 0.004, P = 0.019 and
P < 0.001), and AKP, γ-GT, and pancreatic lipase in the je-
junum (P = 0.007, 0.008 and 0.004). The low GLP-2 treat-
ment pigs had increased activity of AKP and pancreatic
lipase in the duodenum (P < 0.001 and P = 0.019). No sig-
nificant differences were observed in the activity of duo-
denal and jejunal Na+-K+-ATPase and jejunal amylase
between the GLP-2 treated groups and the LPS group.
Discussion
Alteration of plasma GLP-2 concentration during the
weaning period
The plasma concentration of GLP-2 in piglets increases
before birth, peaks in 1-d-old suckling piglets, and de-
creases with weaning-related anorexia [6]. In this study,
the plasma GLP-2 concentration declined abruptly after
weaning, when intestinal adaptation occurred. Addition-
ally, the decreased GLP-2 was followed by decreased di-
gestibility and absorptivity. These findings reveal a
relationship between the GLP-2 level and intestinal
adaptation. Previous studies showed that supplementa-
tion of enteral nutrients or exogenous GLP-2 induced an
increase in plasma concentration of GLP-2 in neonatal
piglets and rats with intestinal injury or short bowel syn-
drome [3, 4, 12]. Similarly, in the present study, injection
of a high dose of GLP-2 significantly prevented the de-
cline of basal levels of plasma GLP-2 and increased the
GLP-2 above the weaning level. Although exogenous
GLP-2 was administered for only the first 7-day, GLP-2
levels remained high in the GLP-2-treated groups on d
14. Moreover, on d 15, LPS-induced mucosal injury was
alleviated in both GLP-2-treated groups. GLP-2 plasma
levels likely remained high because long-term injection
of exogenous GLP-2 promotes not only the recovery of
intestinal adaptability after weaning, but also the piglets’
capacity to secrete endogenous GLP-2. The latter effect
may be attributed to the ability of GLP-2 to stimulate
proliferation and differentiation of intestinal epithelial
cells. However, the mechanism of action for this en-
dogenous effect remains unclear. Therefore, current ef-
forts to increase circulating levels of GLP-2 in order to
modulate the intestinal environment are likely to involve
exogenous supplementation of GLP-2.
Effect of GLP-2 on gut weight and morphology
Weaning of piglets is associated with gross changes in
small intestinal morphology and structure, including vil-
lous atrophy, decreased villus height, and increased crypt
depth, resulting in decreased intestinal active absorption
[13]. Many animal models have demonstrated a signifi-
cant correlation between exogenously administered
GLP-2 and increased growth parameters of the small
and large intestines. For example, in one study, supple-
mental enteral nutrients and exogenous GLP-2 acted in
synergy to induce dramatic mucosal growth in rats [4].
In other studies, GLP-2 infusion at various dosages in-
creased small intestinal mucosal weight [14], DNA and
protein content, and villus height in neonatal piglets [3].
In agreement with these previous reports, our current
study demonstrates that high GLP-2 induced marked in-
creases in the duodenal, jejunal and ileal weight, as well
as the gross weight of the SI, and the SI weight index.
However, the ileal weight showed no significant increase
in the low GLP-2-treated piglets. The explanation for
this may be due to the dose-dependent effect of GLP-2
[3], and the highly tissue-specific distribution of the
GLP-2 receptor (GLP-2R), which is known to be pre-
dominantly localized to the duodenum and jejunal [15].
The architecture of the villus-crypt of the small intes-
tine reflects the health of the small intestine. Similar to
the report of Zhu et al. [9], the present study reports
that LPS causes morphologic changes associated with in-
testinal mucosal injury, such as desquamation of epithe-
lium at the tip of the villus and villous atrophy.
Glucagon-like peptide 2 prevented LPS-induced effects,
including desquamation of villous epithelium, and in-
creased villous height and VCR of the duodenum and
ileum. We conclude, therefore, that GLP-2 alleviates
damage to the intestinal villi. This suggests that GLP-2
can promote the development of villus-crypt architec-
ture and can enhance the barrier function of the intes-
tinal mucosa. These experimental results are consistent
with the findings of Drucker et al. [16] and are also con-
sistent with previous reports that GLP-2 prevents small
intestinal atrophy in total parenteral nutrition (TPN)-fed
neonatal piglets [17]. The effects of GLP-2 in these stud-
ies may be attributed to its ability to increase small in-
testinal mesenteric blood flow [18, 19], stimulate
intestinal cell survival and proliferation, and suppress
cell apoptosis and proteolysis [20, 21].
Effect of GLP-2 on enzyme activity
Prevention of intestinal villous atrophy can improve nutri-
ent digestion and absorption of weaned piglets and elimin-
ate their growth gap [2]. In the current study, we measured
the activity of several duodenal and jejunal enzymes, in-
cluding mucosal AKP, γ-GT, Na+-K+-ATPase, pancreatic
amylase and lipase. Interestingly, lipase activity was greatly
improved by GLP-2 treatment. This may be due to the abil-
ity of GLP-2 to promote the secretion of pancreatic lipase
in the intestine by increasing pancreatic blood flow [22]. In
addition, the activity of duodenal and jejunal AKP and γ-
GT was increased significantly by GLP-2 treatment.
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Intestinal AKP is an enzymatic marker for intestinal mu-
cosa, reflecting epithelial proliferation and intestinal absorb-
ance capacity [23]. Many animal studies have demonstrated
a positive effect of GLP-2 on intestinal enzymes. Glucagon-
like peptide 2 increased jejunal maltase-glucoamylase and
sucrase-isomaltase mRNA abundance and activity levels in
parenterally-fed premature neonatal piglets [14]. Glucagon-
like peptide 2 protected against TPN-induced intestinal
hexose malabsorption [24] and acutely stimulated intestinal
glucose utilization in TPN-fed piglets [25]. In addition,
treatment of weaned piglets with polyethylene glycosylated
porcine GLP-2 increased sucrase activity in the jejunum
and lactase activity in the duodenum and jejunum [26].
Therefore, GLP-2 promotes digestive and absorptive intes-
tinal functions. The specific mechanism of action of GLP-2
is not yet clear, but it is thought to be related to increases
in blood flow [22], plasma GLP-2 concentration, and GLP-
2R expression [27].
Effect of GLP-2 on growth performance
Weaning stress can temporarily inhibit piglet growth.
The present work shows that GLP-2 improves the
growth performance of weaned piglets, as seen in the in-
creased ADG and G:F. Previous experiments in rats have
also demonstrated a similar effect of GLP-2 on growth
performance. Whether administered immediately or de-
layed until inflammation was observed, GLP-2 treatment
significantly increased animal BW [28]. Continuous infu-
sion of GLP-2 at a dose of 240 μg/kg per day induced in-
testinal growth and increased weight gain in a rodent
model of TPN mucosal atrophy [29]. The growth-
promoting effects of GLP-2 may be largely attributed to
the improvement of intestinal development by GLP-2.
Tang-Christensen et al. [30], Dalvi, Belsham [31], and
Guan et al. [32] have demonstrated that GLP-2 is a spe-
cific neurotransmitter that inhibits rodent feeding behav-
ior. GLP-2 is a potent anorexigenic peptide in the brain,
and it can up-regulate mRNA levels of hypothalamic
neuropeptides involved in appetite regulation in chicks
[33]. Peripheral administration of GLP-2 reduced food
intake in mice in the short term (Baldassano et al.,
2012). However, in the current study, there was no dif-
ference in ADFI among the four treatments at d 0 to 7,
7 to 14 as well as d 0 to14 (pre-challenge). This is in ac-
cordance with previous reports indicating that peripheral
administration of GLP-2 did not influence appetite and
ad libitum food intake in humans [34]. The reason for
this discrepancy may be that at physiological concentra-
tions, circulating GLP-2 does not seem to play a signifi-
cant role in appetite regulation [35].
Conclusions
GLP-2 improves growth performance, promotes the
development of intestinal morphology, and enhances
the activity of digestive and absorptive enzymes in
weaned piglets. Exogenous administration of GLP-2
(10 nmol/kg) promotes the secretion of endogenous
GLP-2 to increase the basal level of GLP-2 and pro-
motes the maintenance of GLP-2 levels even after ex-
ogenous supplementation has ceased. The mechanism
by which GLP-2 enhances the activity of digestive and
absorptive enzymes warrants further study.
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